Aligos Therapeutics to Present Multiple Posters at AASLD’s The Liver Meeting® 2023, Highlighting Progress for Its Clinical Stage Portfolio, including Lead THR-β AgonistTHR-β Agonist for the Treatment of NASH, ALG-055009; ALG-000184, the Company’s Lead CAM-E Molecule, and Updates on Several Preclinical Candidates for the Treatment of Chronic Hepatitis B, in Addition to the Recently Announced Late Breaker Poster (#5028-C) SOUTH SAN FRANCISCO, Calif., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today announced that the company is presenting six posters at the American Association for the Study of Liver Diseases’ (AASLD) The Liver Meeting® 2023, taking place in Boston, Massachusetts, November 10 – 14, 2023. The posters, which include both clinical and preclinical data on the nonalcoholic steatohepatitis (NASH) program, ALG-055009, currently in Phase 2-enabling studies, as well as preclinical and clinical data from the chronic hepatitis B (CHB) portfolio, will be available on the Aligos website in the Scientific Presentations & Conferences section following the conclusion of the conference. Poster Details (all times are ET)
Presenter: Stanley Wang, M.D., Ph.D.
Date and Time: Saturday, November 11, 1-2 pm
Presenter: Dinah Misner, Ph.D.
Date and Time: Saturday, November 11, 1-2 pm
Title: Preclinical resistance profile and antiviral activity of the best-in-class CAM-E ALG-001075, the parent compound of ALG-000184 Presenter: Andreas Jekle, Ph.D.
Date and Time: Friday, November 10, 1-2 pm
Title: Class A CAMs induce cell death through HBV core protein aggregation and potentially activate the innate immune response Presenter: Taverniti Valerio, Ph.D.
Date and Time: Friday, November 10, 1-2 pm
Presenter: Junqi Niu, M.D.
Date and Time: Friday, November 10, 12-1 pm
Presenter: Tongfei Wu, Ph.D.
Date and Time: Friday, November 10, 1-2 pm
Forward-Looking Statement
This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this press release that are not historical facts may be considered “forward-looking statements.” Forward-looking statements are typically, but not always, identified by the use of words such as “may,” “will,” “would,” “believe,” “intend,” “plan,” “anticipate,” “estimate,” “expect,” and other similar terminology indicating future results. Such forward looking statements are subject to substantial risks and uncertainties that could cause our development programs, future results, performance, or achievements to differ materially from those anticipated in the forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties inherent in the drug development process, including Aligos’ clinical-stage of development, the process of designing and conducting clinical trials, the regulatory approval processes, the timing of regulatory filings, the challenges associated with manufacturing drug products, Aligos’ ability to successfully establish, protect and defend its intellectual property, other matters that could affect the sufficiency of Aligos’ capital resources to fund operations, reliance on third parties for manufacturing and development efforts and changes in the competitive landscape. For a further description of the risks and uncertainties that could cause actual results to differ from those anticipated in these forward-looking statements, as well as risks relating to the business of Aligos in general, see Aligos’ Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 2, 2023 and its future periodic reports to be filed or submitted with the Securities and Exchange Commission. Except as required by law, Aligos undertakes no obligation to update any forward-looking statements to reflect new information, events or circumstances, or to reflect the occurrence of unanticipated events. cdavis@lifesciadvisors.com